UAE First to Approve Oral Treatment for Non-Segmental Vitiligo

The United Arab Emirates has become the first country worldwide to approve an oral medication for treating non-segmental vitiligo, providing a new systemic therapy option for patients aged 12 years and older.

The Emirates Drug Establishment (EDE) authorized the use of RINVOQ (upadacitinib), a once-daily pill, for adults and adolescents with non-segmental vitiligo whose condition necessitates systemic treatment. Vitiligo is a skin disorder characterized by the loss of pigment in certain areas, resulting in white patches. This occurs due to the destruction of melanocytes, the cells responsible for producing melanin. While the exact cause remains unclear, an autoimmune response is considered a primary factor. The condition is not contagious.

This approval marks a significant advancement by introducing an oral systemic treatment to the existing options available for eligible patients. Previously, treatment methods included topical medications, phototherapy, and laser-based therapies, depending on the type and severity of the condition.

Vitiligo can affect various parts of the body and is often more apparent in individuals with darker skin tones. Since not all white patches are caused by vitiligo, medical evaluation is essential for accurate diagnosis and appropriate treatment selection.

The EDE highlighted that this approval reflects the UAE's progressive regulatory environment and its commitment to embracing global scientific progress, enhancing the pharmaceutical sector, and expediting access to innovative therapies.

The authority also advised individuals noticing unusual changes in their skin color to seek specialist consultation to facilitate early diagnosis and ensure suitable treatment choices.